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Abstract
Headache  disorders,  described  as  early  as  3000  BC,  represent  both  a  treatment
challenge and a serious public  health concern,  with impact  on the individual  and
society. Existing research in primary headache syndromes (not being caused by any
underlying  problem)  focuses  mainly  on  pain  mechanisms.  However,  the  painful
symptomatology is the main encounter for the decreased quality of life and discomfort,
the vegetative manifestations that frequently accompany the cephalalgic syndromes
represent an important source of distress. Despite the advancement of the understand‐
ing  of  the  molecular  basis  of  headache  disorders  and  neurovascular  complex
interactions,  there  is  still  lack  of  a  cohesive  understanding of  the  neurovegetative
modulation  in  different  types  of  primary  cephalalgic  syndromes.  The  aim of  this
chapter is to present an overview of the neurochemical mechanisms and pathways,
which subtend dysautonomic manifestations in headache.
Keywords: headache, autonomic dysfunction, neurovascular system, heart rate varia‐
bility, sympathetic nervous system
1. Introduction
The foundation of our current understanding of the mechanisms of headache dates back to
seventeenth century, when Thomas Willis, one of the great figures in medicine, proposed that
the source of pain was not the brain itself, but nerve fibers being pulled by the distended
vessels. He therefore postulated the vascular theory of headache. It is known today that the
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autonomic manifestations of the vascular headaches are provoked by the tight connections
between the pain receptors located at the head level and the autonomic structures of the
central  nervous  system.  The  primary  cephalalgic  syndromes  with  vascular  implications
(migraine, cluster headache, SUNCT, and paroxysmal hemicrania) present intricate patho‐
genic mechanisms, involving autonomic centers of  the brain stem. Therefore,  headache's
complex manifestations must be understood based on anatomical and physiological correla‐
tions with pain sensitive structures of the cranium.
Primary headaches define “idiopathic” types of cephalgia, which are not the result of an
underlying disease or process. However, these conditions seem to be the result of a complex
interaction among genetic, developmental, and environmental risk factors. The World Health
Organisation (WHO) considers headache disorders as a major public‐health concern, given
the individual and social impact and financial costs to society [1]. Migraine—one of the most
common primary headaches—is now ranked by the WHO as number 19 among all diseases
worldwide causing disability.
During the last years, the classification of headaches has undergone a dynamic process of
restructuration, more detailed specifications to each entity being gradually added, due to the
advancement in the understanding of the pathophysiological mechanisms. The International
Headache Society (IHS) classifies primary headaches into four main categories: migraine (with
its subtypes), tension‐type headache, cluster headache and other trigeminal autonomic
cephalgias, and other primary headaches [2].
Migraine is characterized by attacks of moderate to severe unilateral and pulsatile headache
lasting for 4–72 h, which is often associated with photophobia, phonophobia, nausea, and
vomiting. In migraine with aura, the headache may be preceded by transient focal neurological
symptoms. Trigeminal autonomic cephalalgias (TACs) are a group of primary headaches
characterized by lateralized headache and ipsilateral cranial autonomic features such as
conjunctive injection, lacrimation, and rhinorrhea. The main subtypes are represented by
cluster headache, paroxysmal hemicrania, short‐lasting unilateral neuralgiform headache
attacks with conjunctival injection and tearing (SUNCT)/short‐lasting unilateral neuralgiform
headache attacks with cranial autonomic features (SUNA), and hemicrania continua [2]. The
TACs are distinguished from each other by their attack length, duration, and frequency of
occurrence [2].
Preclinical studies in primary headaches highlighted the complex and intricate mechanisms
involving the anatomy and physiology of trigeminovascular and cranial autonomic systems
responsible for a variety of symptoms [3–5]. The nociceptive innervation of intracranial vessels
and the meninges is based on unmyelinated (C‐fibers) and thinly myelinated (Aδ fibers) axons
containing vasoactive neuropeptides such as substance P (SP) and calcitonin gene‐related
peptide (CGRP) [6]. Besides the trigeminal fibers originating in the ipsilateral trigeminal
ganglion, neurovegetative fibers formed mainly by sympathetic tracts arising mainly from the
superior cervical ganglion and a rather sparse innervation by parasympathetic fibers origi‐
nating in the sphenopalatine and otic ganglia have been described [7, 8]. The innervation of
intracerebral (pial) blood vessels has also an autonomic component, represented mainly by
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parasympathetic fibers coming principally from the internal carotid and sphenopalatine
ganglia [9].
However, despite an increasing body of data concerning the morphofunctional organization
of the pain system in headache, the episodic and rather unpredictable manifestations of most
primary headaches still represent a clinical and therapeutic challenge. There are numerous
hypotheses at different levels, from molecular signaling to brain networks, with more and more
data defining the “pain matrix” as a top‐down system, implying both central and peripheral
structures, from impairment in the functional connectivity during resting state (default mode
network) to neurogenic inflammation mediating vasodilatation and increased permeability of
blood vessels [10, 11].
2. Complex neurovascular interactions in primary headaches: migraine
as a pathophysiological model
Primary headaches share many similarities, primarily trigeminovascular activation. While
migraine is the most studied of all primary headaches, from both a clinical and a preclinical
perspective, there have been advances in our understanding of the pathophysiology of tension‐
type headache and the trigeminal autonomic cephalalgias, through a combination of clinical
studies and preclinical animal models.
Migraine is a complex primary brain disorder that involves a cascade of events that lead to
recurrent inappropriate activations of the trigeminocervical pain system. As any other pain, it
is perceived differently by each patient. Conceived as an alarm system of the body, the pain
may become, at some point, an aggressor factor of the own body by the reflex reactions that it
can trigger. It is well known that the pain perception is dependent not only on the intensity of
the stimulus, but also on a multitude of genetic, psychological associated factors (emotional
state and attention), on anterior experiences, memories, associations with facts of life, and
comorbidities. The stimulation of the nociceptors in teguments, vessels, and joints leads the
stimulus on known sensitive paths toward the parietal cortex, but a series of regulating neural
mechanisms intervene both at the cortical level and on the route of the stimulus, trying to adapt
the perception of the pain sensation to the individual body homeostasis. Which are those
structures and whether they can be influenced represent the concern of scientists for decades.
The meningeal vessels have a motor and sensitive innervation by the trigeminal terminations
(ophthalmic branches for the anterior and posterior compartment, the cervical C2, C3 nerve
roots, with sympathetic fibers from the paravertebral sympathetic chain‐contributing for the
posterior part), which, in the end, establish connections with the secondary trigeminal neurons
from the caudal trigeminal nucleus. Trigeminal nucleus is made up of the spinal portion in the
converging information about pain and temperature and the pontine region with tactile
information. The dendrites of the bipolar neurons from Gasser ganglia receive input from the
pain receptors of dura mater and craniofacial structures, but also from the vascular wall and
they direct it to trigeminal nucleus, thalamus, and contralateral parietal cortex (and in the same
time collateral projections also target mesencephalic nuclei), including the dorsal reticular
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nucleus (DRt), the rostral ventral medulla (RVM), and the midbrain periaqueductal gray
(PAG) [12–14].
The motor component of the cerebrovascular system implies an extrinsic innervation of the
meningeal vessels, from the cervical (sympathetical), otic, sphenopalatin, and trigeminal
ganglia (parasympathetical) and an intrinsic innervation for the small intraparenchimatous
vessels, derived from brain stem nuclei such as locus coeruleus [15].
Cerebral blood flow (CBF) is regulated by vasomotor, chemical, metabolic, and neurogenic
mechanisms, but under normal physiological conditions neurogenic control has little influence
on cerebral autoregulation as other methods of control are dominant [16].
There is considerable experimental literature to document that stimulation of trigeminal
afferents can result in cranial autonomic outflow, the trigeminal–autonomic reflex.
From the time of the stimulation of the nociceptive endings until the perception of the pain
sensation, the transmission of the signal is modified by a series of mechanisms with the final
aim of improving the painful sensation.
3. Nociceptive system modulation in primary headaches
Known in a great measure, the endogenous antinociceptive system is organized on three levels:
first, supraspinal descending inhibition; second, segmental spinal inhibition (inhibitor
complex of the pain in the posterior horn of the spine), and third, propriospinal, heteroseg‐
mental inhibition‐supraspinal descending inhibition system.
The experimental studies, using pharmacological techniques, inhibitors, electrical stimulators,
and functional neuroimaging techniques, revealed the existence of a complex system of pain
modulation, a real neuronal matrix that is highly activated at the arrival of a nociceptive
stimulus. This network is a dynamic and plastic connection between different neuronal relays
and it is also involved in other higher nervous activities: cognition, emotion, and motivation.
The pain network, with an anatomical basis still partially known, involves a series of neuro‐
modulators and receptors and may be influenced both pharmacologically (including opiates,
cannabinoids, NSAIDs, and serotonin/norepinephrine reuptake blockers) and mentally and
emotionally, ultimately determining the sensation of pain [17].
Anatomically, the parietal cortex 1 and 2, insular lobe, thalamus, hypothalamus, amygdala,
and the rostral anterior cingulate cortex (rACC) send messages to the periaqueductal gray
matter (PAG) from where the descending inhibitor stimulus is transmitted to the trunk (sensory
trigeminal core) and rostral bone marrow, with descending inhibitory projection on the
medullar posterior horn.
The periaqueductal gray matter is a real center for holistic integration of the painful
sensation because it has connections with the prefrontal cortex and amygdala, which, in
turn, have a recognized role in the integration of emotions, anxiety, and risk assessment
with avoidance [18].
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Fields et al. [19] have identified in the rostral cervical region the existence of two neuronal
populations with different functional roles: population “on” which increases its discharges
before initiating the nociceptive reflex, and the population “off” which reduces its discharges
when responding to the pain and whose activation produces analgesia. The population “on”
is represented by the μ‐opioid receptors whose activation inhibits the discharges of these
neurons. Opioids and cannabinoids inhibit pain by enhancing the baseline firing rate of “off”‐
cells and eliminating the “off”‐cells pause in response to nociceptive stimuli [20]. In these
interdependent connections, a series of neuromediators may have multiple actions, such as
serotonin and norepinephrine, but also other aminergic systems.
The PAG and RVM stimulation determine the release of serotonin, as the nucleus raphe
magnus located near the trigeminal nucleus, in the bilateral inferior arch, releases serotonin
with a possible role in the process of endogenous analgesia. The functional neuroimaging using
BOLD technique revealed the activation of the nucleus as answer to the trigeminal painful
stimulation suggesting its role [14, 21, 22].
Conversely, the implication of serotonin in stimulating the PAG and RVM neurons is not fully
understood, but it is obvious that other nonserotonergic systems are involved in modulating
the pain. Serotonin could be both inhibitory and facilitating the pain depending on the
subtype of receptors excited. That GABAergic and glycinergic projections from the RVM
mediate antinociception [23].
Norepinephrine released by the locus coeruleus and Kölliker‐Füse nuclei under the impulses
arrived from PAG and RVM seem to have a strong antinociceptive role by blocking the pre‐
and postsynaptic receptors of the spinal neurons involved in transmitting the pain or by
stimulating the alpha‐2‐adrenergic receptors and indirectly by stimulating the alpha‐1‐
receptors, which will cause the depolarization of inhibitory GABAergic neurons [23].
3.1. Segmental spinal inhibition
At the posterior horn of the spine, the endogenous antinociceptive system is represented by
interneurons and the supramedullary descending endings. The opioids act on μ receptors
located on the presynaptic endings of the related fibers where it blocks the calcium channels
and open the potassium channels producing a hyperpolarization by inhibiting the release of
neurotransmitter and thus analgesia. The endogenous analgesic system that is usually inactive
and whose center is PAG projects from it axons (enkephalin conductors) to the raphe magnus
nucleus, and from here to the interneurons from the posterior horn where they can secrete
serotonin facilitating the release of enkephalins from the spinal interneurons. The interneurons
receive external nociceptive fibers and the enkephalins from the two sources are blocking
presynaptically the nociceptive signal. The stimulation of the opioid receptors from the related
nociceptive fibers by enkephalin will determine the same blockage of the calcium channels
whose activation is also necessary for releasing the substance P [24]. Supraspinal descending
inhibition may not only depress mean discharge rates of nociceptive spinal dorsal horn
neurons, but also may modify harmonic oscillations and nonlinear dynamics (dimensionality)
of discharges [25].
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3.2. Propriospinal, heterosegmental inhibition
Besides the classical, local, segmental, and supraspinal descending systems, it seems that there
is a third endogenous antinociceptive system: propriospinal, intersegmental system inhibiting
the nociceptive neurons in the dorsal horn. It seems to modulate partially the descending
pathways and it is activated by conditioning (stimulating) the heterosegmental painful stimuli
causing a neuronal constrastimulation (counterirritation) [25].
This multistage organization of the endogenous antinociceptive system can be influenced with
beneficial results or it can be demodulated resulting in pain exacerbation.
The new functional neuroimaging techniques have showed the influence of the placebo‐type
psychogenic factor that cause the activation of the descending inhibitory network with the
stimulation of the μ‐opioids in rostral anterior cingulate cortex (rACC), the posterior cingulate
cortex(PCC), the dorsolateral prefrontal cortex, and the anterior insular cortex with the increase
of the blood flow in PAG also. Similarly, the reverse reaction of waiting, anticipation of a painful
sensation determines a tendency to inhibition similar to that of an intense stimulation (nocebo
effect) [26].
In patients with migraine, interictal, the functional MRI studies revealed an increase in the
nociceptive diffuse activity mediated in different ways [27]. Another way of modulating pain
is represented by “the nociceptive diffuse control of the pain.” The concept, issued by Le Bars
since the 8th decade of the last century refers to the wide dynamic range inhibition of neurons
from the dorsal horn responsive to a painful stimulation by a nociceptive stimulus applied
elsewhere in the body. The inhibition mechanism seems to be central and its loss is involved
in the chronic painful syndromes, but also in the becoming chronic and of medication‐overuse
headache [28, 29]. This system is integrated in the dorsal reticular nucleus which receives
nociceptive information from the marrow and communicates with PAG and RVM, amygdala,
thalamus, and finally inhibiting the marrow by descending projections. The neurons in dorsal
reticular nucleus (DRt) establish connections with the cortex and multiple central nervous
system areas involved in modulating the pain–the spino‐supraspinatus loop [30].
Perrotta et al. [31] found the existence of a process of central sensitizing of the pain pathways,
with the abnormal and facilitating processing of the stimuli in the trigeminal nucleus both in
crisis and interictally, suggesting a chronic hyperexcitability possibly conditioned genetically
with dysfunctional consequences on the antinociceptive modulating system [32].
It is possible that this demodulation of the nociceptive stimulus processing to be due to a defect
of the default mode network, claim supported by the neuroimaging morphofunctional studies
which revealed metabolic changes in the brain areas involved in processing the pain. The
default mode network consists of a series of relays (part of the medial temporal lobe, part of
the medial prefrontal cortex, and the posterior cingulate cortex, along with the adjacent ventral
precuneus and the medial, lateral, and inferior parietal cortex) whose anatomical bases are
intertwined with the pain processing pathways. The current data suggest that the network is
active when the individual is not focused on the outside world and the brain is at wakeful rest
and it is possible that it participates in the basic settings of the main brain functions [33].
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The hypothalamus, the vegetative brain, establish direct anatomical connections with the
trigeminal structures and it is involved in a variety of cerebral functions with vegetative
component including regulating the vasomotricity and processing of pain, maintaining the
homeostasis. The recent studies have found that there is a disorder of its functional connectivity
with the vegetative structures, in the sense of its increasing or decreasing, all being able to
disorder the processing of exteroceptive stimuli, especially those painful [34–37].
The hypothalamus is also connected with the sympathetic cerebral structures, such as the
parahippocampal gyrus and cerebellar peduncle. The accentuation of connectivity with these
centers, found in patients with migraine could prevail in the cortical answer to external
nociceptive stimuli. The finding was made by BOLD neuroimaging studies, by increasing the
activity in these structures both in sympathetic stimulation and at rest. Similarly, there have
been found hyperexcitable connections (enhanced functional connectivity) with parasympa‐
thetic structures (temporal pole, superior temporal gyrus, and cerebellar lobules V and VI)
ultimately determining a disorder of the processing of internal stimuli in patients with
migraine, explaining some features of reaction of the patient to external stimuli [38].
Locus coeruleus, the largest noradrenergic nucleus in the brain is connected by anatomical
structures with the hypothalamus, with which it establishes hyperfunctional connections.
Involved in modulating the neuronal discharges from thalamus and prefrontal cortex as
response to the nociceptive stimuli and in the inhibition of the nociceptive reflexes, it may have
an important role in processing the pain in patients with migraine [39]. The caudate nucleus
recently involved in processing the pain has also hyperfunctional connectivity with the
hypothalamus suggesting an involvement in the chronobiology of migraine [40].
On the other hand, a decrease in the functional connectivity with various cerebral structures
(cortical regions in the frontal and occipital regions) was found where hypofunctions were
found. No one can say for now that hypothalamus plays in migraine a role similar to
vascular face algies, but it certainly interferes with the processing of the pain and it is
responsible for a part of the vegetative manifestations in the migraine and their relationship
with the human psyche. The disorder could be due to the large amount of information
received from the neurons of the spinal trigeminal nucleus, repeated activation during the
attacks, and a phenomenon of central sensitizing of the hypothalamic and autonomic
connections [41].
In addition to the fast synaptic transmission mediated by classic neurotransmitters, the extra
synaptic transmission of chemical signals such as neuropeptides could act a key role for long‐
term effects following intense noxious stimulation. These extra synaptic peptides, among their
intrinsic vascular activity, also increase the excitability of neurons in the dorsal horn and
trigger the expression of the immediate‐early genes, thus changing the underlying chronicity
of the pain.
The transmission of the nerve signal to the trigeminal neurons also involves the presence of
some peptides with strong vasodilatory action of the cerebral vessels, the essential link in the
pathogenesis of the primary cephalalgias. These peptides (calcitonin gene‐related peptide—
CGRP, substance P (SP), and neurokinin A—NKA) are often secreted by the same neuron, in
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different quantities and combinations giving them a remarkable functional diversity. Calcito‐
nin gene‐related peptide is the most potent vasodilator transmitter identified in the cerebral
circulation, and its action is endothelium independent and associated with an increase in vessel
wall cyclic AMP [42–44].
Substance P is a nondecapeptide involved in nociceptive transmission. In many vascular beds,
including the cerebral bed, substance P is a potent vasodilator and it also dilates both arteries
and veins in situ [45]. Substance P can induce protein extravasation in the periphery and a
similar response is seen in the dura with protein extravasation and mast cell degranulation
[46]. Neurokinin A can relax cerebral vessels both in vitro and in vivo, although it is only one‐
tenth as potent as substance P [47]. Both substance P and NKA coexist in perivascular nerve
fibers in peripheral and cerebral vessels [48].
It is possible that the antinociceptive system to be activated not only by direct stimulation, but
also by disinhibition in PAG. By researching the expression of the protein c‐FOS in the activated
neurons, patterns different from the neuronal activity in the structures involved in controlling
analgesia were found. The existence of these patterns different from the neuronal discharge
especially in the spine and finding a background noise have suggested the existence of a tonic
activity of the most nociceptive neurons in the posterior horn of the marrow determined by
the supraspinal continuous discharges of the endogenous antinociceptive system defining the
hypothesis of “prophylactic antinociceptive system” [49].
4. Autonomic system dysfunction in primary headaches
The precise involvement of autonomous nervous system (ANS) in different types of primary
headaches is still a subject of debate, as there is still not a clear‐cut explanation of the differences
found across various studies, both in humans and in animals, concerning the modulation of
sympathetic and parasympathetic nervous system. The different results on dysautonomic
mechanisms in headache patients can be partially explained by the numerous methods used
to quantify the ANS activity, therefore generating specific results for different systems, such
as cardiac (e.g., heart rate variability), cardiovascular (e.g., hypotension), pupillary response,
and also by the different time‐related variations with impact on the vegetative system dynam‐
ics [50, 51].
Autonomic dysfunction of different primary headache types have been investigated in several
studies, most of them analyzing cardiovascular reflex mechanisms or biochemical changes [52–
54]. It is known today that different subtypes of primary headaches share common autonomic
mechanisms implying different endogenous molecules and dysfunctional interactions
between vegetative pathways and brain‐vessel system [55]. Findings indicate as central
mechanisms both sympathetic hyperfunction and parasympathetic hypofunction in autonom‐
ic manifestations of headache patients [56, 57].
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4.1. Sympathetic nervous system and headache
The sympathetic tracts involved in the vascular regulation in headache arise mainly from the
ipsilateral superior cervical ganglion, while some nerve fibers that supply the vertebral and
basilar arteries originate from the inferior cervical ganglion and the stellate ganglion [58, 59].
The vascular dynamics and regulation of the intracranial pressure are mediated by noradre‐
naline (NA) and neuropeptide Y (NPY) [60, 61]. Neuropeptide Y is widely distributed
throughout sympathetic nerve endings together with NA and it is considered a marker of
noradrenergic function. It has been shown that both mediators may be externally influenced,
for instance, by sympathectomize, which in turns, stimulates the expression of parasympa‐
thetic fibers [62]. NPY participates in the autonomic control of cerebral circulation and can be
involved in disorders characterized by neurogenically mediated changes in the cerebral blood
flow, such as migraine, cluster headache, and stroke. Decreased NPY concentrations during
symptoms‐free periods bring further evidence of the dysregulation of the sympathetic function
in the course of migraine. The levels of NPY increase during attacks in migraine patients [63].
Microscopic and functional studies have revealed that NPY expression becomes prominent
with the increase of sympathetic activity [64]. Furthermore, it has been proven that NA
modulates the response of the small pial vessels on the cortical surface and that sympathetic
fibers arise from central sources such as locus coeruleus (LC) or the hypothalamus [65–67].
Therefore, via direct influence, destruction of the LC induces a reduction in the number of
noradrenergic nerve fibers in intracerebral vessels [59], while on contrary that stimulation of
NA neurons in the hypothalamus is associated with an increase in hypothalamic blood flow
which is not influenced by superior cervical ganglionectomy or by the β‐adrenoceptor
antagonist propranolol [68]. These anatomic and physiological features showing central
control may represent possible therapeutic targets in primary headaches.
4.2. Parasympathetic nervous system
As it is well known, cerebral blood vessels display perivascular nerves presenting parasym‐
pathetic activity (mediated by acetylcholine and acetylcholinesterase activity [69, 70]. The vast
majority of parasympathetic nerve fibers to cerebral vessels implied sphenopalatine and otic
ganglia [71]. Interesting enough, it has been shown that parasympathetic nerves may interact
with sympathetic terminals in the close vicinity of the cerebrovascular smooth muscle effector
[71]. Activation of trigeminal nerves and subsequent nociceptive signaling mediates a para‐
sympathetic reflex leading to the release of vasoactive neuropeptides [9, 72, 73]. Vasodilatation
of the cranial vessels seems a common property of cranial neurovascular dynamics involving
sensory and parasympathetic mechanisms [44, 74].
Along with acetylcholine, there are other neuro messengers that mediate neurogenic vasodi‐
latation, such as vasoactive intestinal peptide (VIP), pituitary adenylate cyclase activating
polypeptide (PACAP), and nitric oxide (NO), as demonstrated both by experimental responses
of isolated cerebral arteries and by hemodynamic measurements in vivo [75–77]. VIP is one of
the parasympathetic signaling transmitters contributing to cranial parasympathetic outflow
mediated through the sphenopalatine ganglia. It has been shown that VIP coexists with Ach
in the perivascular nerve fibers around brain vessels [78]. Although, the VIP‐immunoreactive
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nerve supply is sparse in cerebral arteries or veins, it is considered that VIP concentrations are
a marker of parasympathetic activation in migraine [79–81].
4.3. Pathogenic autonomic mechanisms in headache
Large body of data suggests a central role for sensory and parasympathetic mechanisms in the
pathophysiology of primary headaches. Studies have provided support for a dysbalance
between parasympathetic and sympathetic nervous system, which trigger the pathogenic
mechanisms and contribute to the clinical presentation in primary headaches. The activation
of the parasympathetic cranial outflow during migraine and cluster headache (CH) attacks
seems to be due to the activation of the trigeminovascular system, which was described
previously. This implies the release of specific neuromediators, such as the neuropeptide
calcitonin gene‐related peptide (CGRP) [82].
Some studies used transcranial Doppler sonography to assess vascular oscillations corre‐
sponding to myogenic cerebrovascular regulation in migraine and tension‐headache patients
[55, 83]. Most of the data focus on migraine, a chronic neurovascular disorder, which is
classically considered the result of the sympathetic system unbalance, generally meaning
increased sympathetic activity, although some studies showed decreased sympathetic
activity [53, 57]. Both in the prodromal phase and in the headache phase of a migrainous
episode, there are vegetative symptoms, such as hunger, sleepiness, and orthostatic hypoten‐
sion initially, and later, in the headache phase, vomiting and nausea, pointing out a close
relationship between the ANS and this type of headache [2]. The autonomic manifestations
imply decreased plasma noradrenaline levels and increased adrenergic receptor sensitivity
[53]. There are still contradictory data on the exact involvement of sympathetic system in
migraine. Some studies investigated cardiac and cardiovascular reactions during vagal and
sympathetic activation [84]. An increased basal sympathetic tone is also suggested by a
frequent association of hypertension with migraine [85]. However, the association of migraine
with blood pressure variations is still unclear, as there are studies showing an increased
diastolic blood pressure in migraine and also an association of migraine with lower blood
pressure [85]. Sympathetic hypofunction has been reported for migraine in studies of pupil
diameter [82, 86], cardiovascular reflex responses, and heart rate recovery [87]. The heart rate
variability in migraine patients across a longer time period was different compared to healthy
controls during normal daily activity, which pointed out parasympathetic hypofunction in
migraine patients [88].
Sympathetic skin responses [89] and salivary amylase levels as marker of sympathoadrenal
medullary activity [90] seem decreased during migraine attacks, suggesting the dynamic
involvement of the sympathetic system in this pathology.
Gass and Glaros [91] examined different vegetative biomarkers such as the heart rate varia‐
bility, skin temperature, skin conductance, and respiration in patients with migraine and
compared to healthy controls, and found in migraine patients a decreased variability of the
consecutive R‐to‐R intervals, therefore pleading for a sympathetic hyperfunction and de‐
creased parasympathetic tone in migraine patients [91]. Yerdelen et al. [87] examined heart
rate recovery after physical exercise as an index for vagal parasympathetic activity in migraine
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and tension‐type headache patients (TTH) and controls and showed that even though
parasympathetic function has not been affected in migraine and TTH patients, sympathetic
tone in migraine patients is elevated compared to patients with episodic tension‐type head‐
ache [87].
In an interesting study, Tomé‐Pires and Miró [92] measured skin conductance responses (SCRs)
in migraine versus control subjects while presenting pain descriptors, emotional negative
words, and neutral words [92]. The authors showed no differences in the skin conductance
responses in the two groups, but migraineurs recalled more emotional words than controls,
thus suggesting possible new avenues to modulate migraine pain perception and autonomic
responses.
4.4. Cluster headache
This type of headache implies the ophthalmic division of the trigeminal nerve responsible for
the pain manifestations. In addition, there are signs of parasympathetic over activity acting on
the facial and cranial vasculature, such as lacrimation, nasal congestion, and injection of the
eyes [2]. Cranial parasympathetic systems may be involved in mediating these dysfunctions,
with the release of the VIP stimulating vasomotor facial symptoms [93]. Furthermore, it has
been shown that noxious chemical stimulation of rat facial mucosa increases intracranial blood
flow through a trigemino‐parasympathetic reflex, which may explain the involvement of
autonomic pathway [94]. Animal models used superior salivatory nucleus as a model to
measure cranial autonomic symptoms and changes in blood flow in the lacrimal gland/duct
as a measure of cranial autonomic activation [95]. The superior salivatory nucleus projects to
the cranial vessels through the sphenopalatine ganglion, via the greater pietrosal nerve of the
facial nerve. Electrophysiological methods measured neural activity in response to superior
salivatory nucleus stimulation. There were two populations of neurons with differential
latencies in action. The longer latency neuronal response was mediated by activation of the
parasympathetic outflow and that the action of oxygen—as the therapeutic approach, is likely
via this pathway. The shorter latency response seemed most likely via antidromic activation
of the trigeminal autonomic reflex [96]. Moreover, it has been shown also that posterior
hypothalamus may play a central role in the CH, thus explaining the circadian and circannual
periodicity of the symptoms [97].
4.5. Tension‐type headache (TTH)
Although very frequent, the relationship between the tension‐type headache and ANS activity
is less documented [87]. It seems that chronic TTH along with migraine may be associated with
increased sympathetic tonus, expressed by elevated resting heart rate, compared to episodic
TTH [93]. TTH patients may also have a delayed adaptation in heart‐rate to stress and a reduced
pain control system inhibition [97].
Even though the dynamics of ANS intervention in primary headaches is not yet fully under‐
stood, the emergence of translational research models and also the development of new
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techniques to measure the vegetative biomarkers in headaches provide a robust basis for new
and more efficient therapeutic strategies.
5. Heart rate variability as a measure of autonomic nervous system
in migraine
The autonomic nervous system (ANS) has important functions in maintaining homeostasis by
adjustment of the body to internal and environmental demands. Beside key functions con‐
trolled by the ANS such as respiration, blood pressure, heart rate, hormonal regulation, etc.,
ANS is also involved in regulating emotional behavior and cognitive functions.
The sympathetic nervous system (SNS) controls of the heart coming from the upper thoracic
region of the spinal cord. Preganglionic fibers synapse with postganglionic sympathetic fibers
and release acetylcholine, which binds to nicotinic receptors on the postganglionic fibers.
Through sympathetic adrenergic efferent fibers extend to the sinoatrial and atrioventricular
nodes in the heart where they release norepinephrine at synapses with beta‐adrenergic
receptors [98]. Stimulation of the SNS increases heart rate (positive chronotropy), ventricular
contraction (positive inotropy), conduction velocity (positive dromotropy), and rate of
relaxation (positive lusitropy). The parasympathetic nervous system (PNS) control of the heart
coming from vagal nuclei within the medulla oblongata in the brainstem, and efferent nervous
outflow occurs via the 10th cranial nerve (vagus nerve). The long preganglionic efferent nerve
fibers extent to the heart and synapse with a ganglia located near the sinoatrial and atrioven‐
tricular nodes. Acetylcholine is released, binds to nicotinic receptors, and activates short
postganglionic efferent nerve fibers. These postganglionic fibers synapses with muscarinic
receptors in the sinoatrial and atrioventricular nodes, and is activated by acetylcholine. For
heart PNS decreases heart rate (negative chronotropy), force of atrial contraction (negative
inotropy), rate of relaxation (negative lusitropy), and negative dromotropy [98].
The actions of the SNS and PNS are often opposing in their effects and normally the SNS and
PNS activities are in dynamic balance thus indicating a healthy and flexible physiological
system [99]. The autonomic imbalance described by increased SNS activity and suppressed
PNS activity is associated with an increased risk of diseases [99]. The central control of
cardiovascular system involved several areas throughout spinal, bulbopontine, pontomesen‐
cephalic, and forebrain. The medullary centers work through reflex cardiovascular mecha‐
nisms such as baroreflex, chemoreflex, and cardiopulmonary reflex [100]. The afferent fibers
of the cardiovascular reflexes are terminated in the nucleus tractus solitarii [100]. The reticular
formation of the ventrolateral medulla (VLM) is the primary central site that regulates
sympathetic outflow, thus contributing to the regulation of BP and heart rate (HR). In the rostral
VLM part are excitatory neurons which synapse in the intermediolateral gray column of the
spinal cord, and in the caudal VLM are inhibitory neurons that sent projections to the rostral
VLM. The preganglionic parasympathetic neurons located in the nucleus ambiguous and the
dorsal motor nucleus of vagus are involved in the parasympathetic regulation of the cardiac
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reflexes [101]. Also parabrachial nucleus, Kolliker‐Fuse nucleus, the cluster of A5 cells are the
brainstem centers involved in the control of the cardiovascular system.
The upper brainstem level includes the periaqueductal gray matter (PAG), which integrates
the autonomic control with pain modulation and behavioral responses to stress [102]. The
forebrain level includes the paraventricular and related nuclei of the hypothalamus, thalamus,
amygdala, and anterior cingulate cortex, the insular and medial prefrontal cortex that inte‐
grates autonomic and endocrine responses [102]. The anterior limbic circuit (insula, the
anterior cingulate cortex, and amygdala) assures integration of specific sensations with
emotional and goal‐related autonomic responses [102]. Electrical stimulation of the prefrontal
and cingulate cortex, left insula, lateral nucleus of hypothalamus decreased heart rate and
blood pressure, whereas electrical stimulation of right insula, ventromedial nucleus of
hypothalamus increased heart rate and blood pressure [103]. Stimulation of the basolateral
nucleus of amygdala increases blood pressure and decreases heart rate; stimulation of the
rostral nucleus of amygdala results in depressor effects and variable changes in heart rate [103].
The normal sympathovagal regulation induces an increase in heart rate during inspiration and
decrease during expiration, and this physiological phenomenon is known as respiratory
arrhythmia. The intrinsic heart rate is 105 beats/minute while resting heart rate is only 60–80
beats/minute, indicating that the heart is under “vagal dominance” [104].
The electrical signal produced by the heart can be measured with an electrocardiogram.
Electrocardiogram registers depolarization of the atria (P‐wave), depolarization of the
ventricles (the QRS complex), and repolarization of the ventricles (T‐wave). Using these points
we can measure heart period or inter beat interval which measure the time between two
consecutive heart beats in milliseconds [105]. Heart rate (HR) measures the numbers of
consecutive heart beats in 1 min (beats per min). The analysis of consecutive sinus rhythm R‐
R intervals is known as heart rate variability (HRV), a noninvasive electrocardiographic marker
reflecting the activity of the ANS on sinus node function.
HRV parameters can be calculated in time domain (statistical and geometrical), frequency
domain (power spectral density), and nonlinear measures. In time domain methods HRV
parameters are standard deviation between normal intervals during recording—SDNN (ms),
standard deviation of the average values of NN intervals calculated from all 5‐min segments
of the entire recording—SDANN (ms), square root of the mean of the sum of the squares of
differences between adjacent NN intervals—RMSSD (ms), percentage of differences between
adjacent NN intervals differing more than 50 ms—pNN50% [105]. A lot of studies indicate that
SDNN, RMSSD, and pNN50%, time domain indicators of the HRV, represent the activity of
the vagal nerve.
Using simultaneously the Fast Fourier transform method and parametric– autoregressive
method (AR), HRV can be analyzed in frequency domain (power spectral analyses of HRV) in
which can be measured low‐frequency component (LF < 0.15 Hz) taken as an indicator of both
vagal and sympathetic functions, high‐frequency component (HF ≥ 0.15 Hz) as an indicator of
parasympathetic function, very low‐frequency component (VLF—the frequency band in the
range 0.003–0.04 Hz), ultra‐low‐frequency (ULF—the frequency band below 0.003 Hz), and
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the total power (TP) [105, 106]. VLF is related to the thermoregulatory sympathetic vascular
activity and to oscillations in the renin‐angiotensin system [107]. The ratio of LF/HF is
considered as an index of cardiac sympathetic/parasympathetic tone balance.
Abnormalities in the SNS or PNS have been found in migraine patients during the headache‐
free phase [108, 109]. Some researchers revealed sympathetic hypofunction and parasympa‐
thetic hyper‐function in migraine patients during the same period [83, 110]. Other study found
that older patients with migraine may have sympathetic hyper‐function and a parasympathetic
hypofunction during headache‐free intervals [111]. Martin et al. [112] found a reduction of HR
during deep breathing, and after 2 min of tilting. Appel et al. [113] revealed increase of the
low‐frequency band of HRV analysis in migraineurs, suggesting an increase in sympathetic
activity.
We tried to analyze the ANS involvement in migraine using the HRV on long‐term 24‐h ECG.
We investigated 27 subjects with migraine (10 with migraine with aura and 17 without aura)
during headache‐free periods and 10 age‐matched healthy control subjects. We found a
significant decrease in SDNN, RMSSD, and HF indicating parasympathetic dysfunction in
migraine groups during night headache‐free periods, and the most affected were migraine
with aura patients (Figures 1 and 2). LF and LF/HF ratio were increased during the night in
migraine with aura patients (Figures 3 and 4). In both groups of migraine patients, we
discovered an autonomic nervous system dysfunction. The most marked ANS impairment
being present in the group of migraine with aura sufferers where we found sympathetic
hyperfunction associated with parasympathetic hypofunction especially at night with loss of
circadian rhythms [114].
Figure 1. Square root of the mean of the sum of the squares of differences between adjacent NN intervals—RMSSD
(ms) in study groups (C, control group; M, migraine without aura group, MA, migraine with aura group).
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Figure 2. High‐frequency component of power spectral analyses of HRV in study groups.
Figure 3. Low‐frequency component of power spectral analyses of HRV in study groups.
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Figure 4. LF/HF ratio in study groups.
HRV is associated with highly functional prefrontal cortex inhibitory activity over subcortical
structures that make the body to well adapt to the environment. Low HRV is associated with
reduced prefrontal inhibitory control over subcortical structures and failure to recognize safety
signals [104]. Failure of inhibition leads to continue to process fear information and is linked
with anxiety and depression [115]. Chronic psychological stress and depressed mood have
been shown to be associated with SNS dominance and vagal withdrawal, highlighted by
decreased HRV [115, 116]. In our study, we found an increased frequency of anxiety and
depressive symptoms in migraine patients, especially in migraine with aura group [114].
Individuals with high level of stress, anxiety, and depression display an imbalance between
PNS and SNS activities. Prolonged stress may influence health via several different pathways,
i.e., alterations in autonomic nervous system (increased SNS and decrease PNS), neuroendo‐
crine activity, immune, behavioral, and cognitive functions.
Many other factors such as alcohol, nicotine, physical exercise, age, gender, diabetes, hyper‐
tension, cardiovascular disease, sleep apnea, chronic respiratory disease, or medications (sex
steroid hormones, antidepressants, μ‐ blockers, etc.) may influence the autonomic nervous
system [117–121]. Moreover, the ANS exhibits a circadian variation [122].
The ANS involvement during the premonitory phase of a migraine attack is suggested by many
symptoms and signs with potential involvement of the hypothalamus (depression, irritability,
fatigue, food cravings, and increase yawning), brainstem (neck stiffness), and cortex (abnormal
sensitivity to light, sound, and smell) [123]. Nausea, vomiting, dizziness, cutaneous vasocon‐
striction or vasodilation, conjunctival injection, lacrimation, nasal congestion, rhinorrhea,
eyelid edema, piloerection, and diaphoresis can occur during pain phase [108, 109]. Also
accompanying psychological and cognitive symptoms can appear—inability to organize
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thoughts and plans, physical exhaustion, confusion, agitation, aggressiveness, depression, and
anxiety.
Migraine can be initiated by diverse triggers including bright lights, sounds, hunger, and
mental exertion; poor sleep quality, menses, excess consumption of alcohol, chocolate, and
fermented cheese. Sleep usually calms the pain.
In our study when we asked patients about sleep quality and dreaming, they complained about
bad sleep quality. The majority experience negative sensations such as anxiety, fear, or terror
and contents such as perception of fall and unsuccessful efforts to do various things [114].
These observations suggest that there is some malfunction in the prefrontal cortex, limbic
system, amygdala, and hypothalamus, elements involved in dream and migraine pathophysi‐
ology [124]. Activation of the limbic system, amygdala, and anterior cingulate cortex observed
in rapid eye movement sleep are involved in cardiovascular regulation and could reflect
responses to intense emotions such as fear and anxiety found in migraine patients during
night [125].
When physiological stressors, such as migraine attacks, are frequent and persistent allostatic
responses can become maladaptive, resulting in changes of the body system. Migraine patients
were found to have elevated plasma levels of cortisol in headache‐free periods [126] and during
pain period [127]. Increased chronic levels of cortisol can induce atrophy in the PFC, decrease
dopamine in the brain pleasure circuits, deplete the norepinephrine from the LC, and reduce
frontal lobe serotonin receptors levels, thus contributing to flatness of emotion, concentration
weakening, mood dysfunctions, and bad quality of sleep [128]. Neurogenesis and apoptosis
in hippocampus are suppressed [129] and also dysregulation of the autonomic nervous system
and hypothalamic‐pituitary‐adrenal axis with alterations in hormone regulation are revealed
during chronic stress. Chronic migraineurs show decreased amygdala volume [130] that can
be related to the high levels of anxiety or fear in these patients [131]. In chronic migraine, beside
cortisol, other dysfunction in hormone secretion has been reported for prolactin, and melato‐
nin [132]. Sleep deprivation and circadian disruption can have negative consequences for body
functions including increased appetite, increased levels of proinflammatory cytokines,
decreased parasympathetic and increased sympathetic tone, increased blood pressure, and
elevated insulin and blood glucose [133]. Hormonal dysfunctions in estrogen and progesterone
regulation are frequent in migraine patients, and migraine improves after menopause or with
hormonal therapies [134].
The cumulative effects of migraine over the body, as well as its treatment represents allostat‐
ic load [135]. Early interruption of a feed‐forward vicious cycle with different techniques
(medication and stress reduction) is important to diminish allostatic load [135].
6. New directions in the treatment of primary headaches
It is classically accepted that migraine may respond to few different pharmacological agents
such as pain‐relieving medications (like triptans) in acute phase and preventive medication
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like antiepileptics (like topiramate), CH responds to oxygen and parenteral triptans, while
verapamil has the most success for prevention. Paroxysmal hemicrania responds to indome‐
thacin. SUNCT/SUNA responds to lamotrigine and topiramate. Hemicrania continua respond
to indomethacin [136].
6.1. Neurostimulation
A promising and rather new venue in headache treatment seems to be represented by
neuromodulation of pain central system and autonomic pathways. These noninvasive
methods may provide relief in patients with chronic and pharmacoresistant forms of headache.
Therefore, it was reported that transcutaneous stimulation of the parasympathetic nerve
system via the vagus nerve can abort migraine attacks [137]. Vagal nerve stimulation represents
a well‐established nonpharmacological strategy in epileptic patients with intractable seizures
and also in depressed patients. Some cohorts of epileptic patients with implanted VNS have
shown improvement in their migraine symptoms, but the eventual causality with seizure
frequency reduction still needs to be debated also [138]. Similarly, patients known with
migraine and treated with VNS for depression experienced an improvement in the migraine
attacks [139]. Yet, further studies need to clarify the exact correlation between VNS effects and
migraine mechanisms.
Recently, it has been shown that patients with CH seem also to benefit from noninvasive VNS,
with improvement of their initial condition of approximately 50% [140]. On the other hand,
occipital nerve stimulation (ONS) has proved favorable clinical results in the treatment of
refractory chronic CH in well‐documented cases, but there are still limited studies in this
direction. The hypothalamic activation during cluster attacks led to the introduction of deep
brain stimulation (DBS) technique for refractory CH, with rather positive effects. Still, there is
need of further confirmation of this method in CH, in terms of targeted anatomo‐functional
centers and patients selection in order to have a good risk/benefit outcome [141, 142].
6.2. Modulation of signaling molecules
Migraine is considered as a syndrome of chronically low central serotonin system with
consequent 5‐HT receptor hypersensitivity, with migraine attacks triggered by a sudden
increase in 5‐HT release [143]. Therefore, medication targeting specific serotoninergic path‐
ways showed its efficiency in migraine acute treatment. Triptans are selective serotonin
agonists, specifically acting at 5‐hydroxytryptamine 1B/1D/1F (5‐HT1B/1D/1F) receptors on
intracranial blood vessels and sensory nerve endings. The first combination product of a triptan
and a nonsteroid anti‐inflammatory drug (naproxen) was approved by the U.S. Food and Drug
Administration in April 2008. It has been proven that migraineurs who experienced poor
response to a short‐acting triptan, the combination of sumatriptan/naproxen sodium reported
more effective results in pain reduction and migraine‐associated symptoms of photophobia
and phonophobia [144].
New prevention strategy via biochemical signaling in migraine prevention is based on
monoclonal calcitonin gene‐related peptide (CGRP) antibodies to CGRP are effective in
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migraine prophylaxis [145]. As shown previously, robust data showed that neuropeptides
present in the perivascular space of cranial vessels are important mediators of nociceptive
input during migraine attacks. Pituitary adenylate cyclase‐activating polypeptide (PACAP) is
present in sensory trigeminal neurons and may modulate nociception at different levels of the
nervous system. It has been proposed that the PAC(1) receptor represents a possible signaling
pathway implicated in migraine and may be a future pharmacological target in migraine
treatment [146].
The precise implication of the hypothalamus in premonitory phases of migraine and also
during migraine attacks is discussed. Therefore, novel targets may include hypothalamic
peptides such as orexine, which interferes with trigeminal nociceptive activity and cortical
spreading depression–the well‐known neural phenomena in the prodromal phase of mi‐
graine [147]. Interestingly, Botulinum toxin A was associated with a small or modest benefit
for chronic daily headaches and chronic migraines, reducing headache episodes per month
[148].
6.3. Genetic therapies
Genetic studies have highlighted a potential role in the etiopathogenesis of primary headaches
for several genes related to vascular, neuronal, and neuroendocrine mechanisms. Therefore,
recent data showed the implication of new genes, like methylenetetrahydrofolate reductase
(MTHFR), potassium channel, subfamily K member 18 (KCNK18), transient related potential
vanilloid type 1 (TRPV1), transient related potential vanilloid type 3 (TRPV3), hypocretin
(orexin) receptor 1 (HCRTR1), and hypocretin (orexin) receptor 2 (HCRTR2), both in migraine
and cluster headache. Of course, further preclinical and clinical data need to confirm the precise
place and indication of genetic intervention when addressing primary headaches, thus
promoting the multifactorial determination of this pathology [149].
6.4. Multidisciplinary nonpharmacological interventions
Behavioral and psychological coaching in chronic headache patients in a multidisciplinary
setting may foster treatment adherence and improve the quality of life in these patients. It is
considered that behavioral therapy combined with pharmacological intervention (for example,
beta blocker alone) renders more effective treatment [150].
The above‐mentioned directions of treatment in primary headache highlight the complexity
of the pathogenic mechanisms of this pathology and the need for further studies to address
therapeutic strategies adapted to individual condition.
7. Conclusions
Headache disorders represent both a treatment challenge and a serious public health con‐
cern, with major impact on the individual and society. Although the painful symptomatol‐
ogy is the main encounter for the decreased quality of life and discomfort, the vegetative
Primary Headaches and their Relationship with the Autonomic Nervous System
http://dx.doi.org/10.5772/65737
63
manifestations which frequently accompany the cephalalgic syndromes, cause an impor‐
tant amount of distress. Despite the advancement of the understanding of the molecular
basis of headache disorders and neurovascular complex interactions, both at central and
peripheral levels, especially concerning migraine, there is still lack of an integrated view of
the neurovegetative modulation in different types of primary cephalalgic syndromes, trans‐
lating from animal pathophysiologic “models” to clinical data. As shown in this chapter,
the neurochemical mechanisms which subtend dysautonomic manifestations in different
types of headache share common pathways, yet there is need to specifically address the
various vegetative biomarkers in each type of headache, in order to provide more efficient
and individualized therapeutic strategies, combining multimodal pharmacological and
nonpharmacological approaches.
Without pretending exhaustively, this chapter highlights the need for a better and a more
accurate characterization and classification of primary headaches, taking into consideration
the whole spectrum of clinical manifestations, including the dysautonomic activity. Despite
locally derived, population‐based data describing the burden of primary headache disorders,
there is still need of a global perspective on disease impact, through both preclinical and clinical
data, in both developed and developing countries, in order to maximize efforts for a better
understanding and management of the disease.
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